Sequencing efforts have primarily focused on low-grade meningiomas, while characterization of high-grade and/or metastatic tumors remains relatively infrequent (7); however, integrated genomic analyses have highlighted key pathways, such as the co-mutation of SMARCB1 in atypical meningiomas (13). The gene discussed is SMARCB1; the disease is meningioma.